PT3221298T - Derivados de 4-oxo-3,4-di-hidro-1,2,3-benzotriazina como moduladores de gpr139 - Google Patents

Derivados de 4-oxo-3,4-di-hidro-1,2,3-benzotriazina como moduladores de gpr139

Info

Publication number
PT3221298T
PT3221298T PT15816275T PT15816275T PT3221298T PT 3221298 T PT3221298 T PT 3221298T PT 15816275 T PT15816275 T PT 15816275T PT 15816275 T PT15816275 T PT 15816275T PT 3221298 T PT3221298 T PT 3221298T
Authority
PT
Portugal
Prior art keywords
gpr139
modulators
hydro
oxo
benzotriazine derivatives
Prior art date
Application number
PT15816275T
Other languages
English (en)
Portuguese (pt)
Inventor
Hitchcock Stephen
Monenschein Holger
Reichard Holly
Lam Betty
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of PT3221298T publication Critical patent/PT3221298T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08—Radicals containing only hydrogen and carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/08—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 condensed with carbocyclic rings or ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Addiction (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PT15816275T 2014-11-20 2015-11-19 Derivados de 4-oxo-3,4-di-hidro-1,2,3-benzotriazina como moduladores de gpr139 PT3221298T (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462082539P 2014-11-20 2014-11-20
US201562184729P 2015-06-25 2015-06-25

Publications (1)

Publication Number Publication Date
PT3221298T true PT3221298T (pt) 2019-06-28

Family

ID=55022667

Family Applications (2)

Application Number Title Priority Date Filing Date
PT15816275T PT3221298T (pt) 2014-11-20 2015-11-19 Derivados de 4-oxo-3,4-di-hidro-1,2,3-benzotriazina como moduladores de gpr139
PT191520360T PT3536324T (pt) 2014-11-20 2015-11-19 4-oxo-3,4-dihidro-1,2,3-benzotriazinas como moduladores de gpr139

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT191520360T PT3536324T (pt) 2014-11-20 2015-11-19 4-oxo-3,4-dihidro-1,2,3-benzotriazinas como moduladores de gpr139

Country Status (40)

Country Link
US (5) US9556130B2 (enExample)
EP (2) EP3536324B1 (enExample)
JP (2) JP6637501B2 (enExample)
KR (1) KR102582021B1 (enExample)
CN (2) CN112062730B (enExample)
AU (1) AU2015349866B2 (enExample)
CA (1) CA2968242C (enExample)
CL (1) CL2017001292A1 (enExample)
CO (1) CO2017005959A2 (enExample)
CR (1) CR20170275A (enExample)
CY (2) CY1122613T1 (enExample)
DK (2) DK3536324T3 (enExample)
DO (1) DOP2017000120A (enExample)
EA (1) EA033728B1 (enExample)
EC (1) ECSP17038999A (enExample)
ES (2) ES2897545T3 (enExample)
GE (2) GEAP201814515A (enExample)
HR (2) HRP20191003T1 (enExample)
HU (2) HUE057451T2 (enExample)
IL (1) IL252311B (enExample)
JO (1) JO3719B1 (enExample)
LT (2) LT3536324T (enExample)
MA (1) MA40993B1 (enExample)
MD (1) MD3221298T2 (enExample)
MX (1) MX378158B (enExample)
MY (1) MY187423A (enExample)
NZ (1) NZ732208A (enExample)
PE (1) PE20170899A1 (enExample)
PH (1) PH12017500920A1 (enExample)
PL (2) PL3536324T3 (enExample)
PT (2) PT3221298T (enExample)
RS (2) RS59078B1 (enExample)
SG (1) SG11201704002UA (enExample)
SI (2) SI3536324T1 (enExample)
SM (2) SMT202200142T1 (enExample)
TN (1) TN2017000196A1 (enExample)
TW (1) TWI684590B (enExample)
UA (1) UA120375C2 (enExample)
UY (1) UY36406A (enExample)
WO (1) WO2016081736A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3719B1 (ar) * 2014-11-20 2021-01-31 Takeda Pharmaceuticals Co 4- أوكسو-4،3- داي هيدرو-3،2،1- بنزوترايازينات كمواد ضابطة لأجل gpr139
US12042496B2 (en) 2018-10-16 2024-07-23 The University Of Florida Research Foundation, Incorporated Methods related to opioid therapeutics
WO2020097609A1 (en) 2018-11-09 2020-05-14 Blackthorn Therapeutics, Inc. Gpr139 receptor modulators
CR20220160A (es) * 2019-09-16 2022-06-16 Takeda Pharmaceuticals Co Derivados de piridazin-3(2h)-ona fusionados con azol
WO2021127459A1 (en) * 2019-12-20 2021-06-24 Blackthorn Therapeutics, Inc. Gpr139 receptor modulators
WO2021224680A1 (en) * 2020-05-08 2021-11-11 Takeda Pharmaceutical Company Limited Substituted benzotriazinone metabolites of a gpr139 agonist
US20230310441A1 (en) * 2020-09-21 2023-10-05 Takeda Pharmaceutical Company Treatment for schizophrenia
US11760788B2 (en) 2021-03-02 2023-09-19 Pathways Neuro Pharma, Inc. Neuroreceptor compositions and methods of use
CN116693536A (zh) * 2022-03-01 2023-09-05 上海科技大学 吡咯并三嗪酮类化合物、含其的药物组合物、其制备方法及其应用
CN116693545A (zh) * 2022-03-01 2023-09-05 上海科技大学 噻吩并含氮杂环类化合物、含其的药物组合物、其制备方法及其应用
CN117986183A (zh) * 2022-10-28 2024-05-07 浙江友宁生物医药科技有限公司 一种gpr139受体激动剂、其制备方法及其应用
WO2024102802A1 (en) * 2022-11-11 2024-05-16 Takeda Pharmaceutical Company Limited Zelatriazin for the treatment of depression
WO2025119351A1 (zh) * 2023-12-08 2025-06-12 深圳湾实验室 Gpr139激动剂
WO2025162441A1 (zh) * 2024-02-02 2025-08-07 上海科技大学 稠杂环类化合物与其制备方法、药物组合物及应用
CN121159462A (zh) * 2025-11-19 2025-12-19 杭州市第七人民医院(杭州市心理危机研究与干预中心) 喹唑啉酮类化合物及其在制备神经系统疾病药物中的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3794726A (en) * 1972-08-21 1974-02-26 Uniroyal Inc Inhibiting aggressive behavior with 1,2,3-benzotriazin-(3h)-one
WO1987004928A1 (fr) 1986-02-24 1987-08-27 Mitsui Petrochemical Industries, Ltd. Agents therapeutiques de la neuropathie
EP0315390B1 (en) * 1987-11-04 1994-07-20 Beecham Group Plc Novel 4-oxobenzotriazines and 4-oxoquinazolines
CA2526506A1 (en) 2003-06-09 2004-12-16 Boehringer Ingelheim International Gmbh Inhibitors of papilloma virus
AU2004261283B2 (en) 2003-07-31 2008-05-01 Irm, Llc Bicyclic compounds and compositions as PDF inhibitors
FR2875805B1 (fr) 2004-09-27 2006-12-29 Genfit S A Composes derives de n-(benzyl) phenylacetamide substitues, preparation et utilisations
TW200736227A (en) 2005-12-23 2007-10-01 Astrazeneca Ab New compounds III
TWI433839B (zh) 2006-08-11 2014-04-11 Neomed Inst 新穎的苯并咪唑衍生物290
MX2009010218A (es) * 2007-03-23 2009-10-19 Hoffmann La Roche Derivados de aza-piridopirimidinona.
WO2009086303A2 (en) * 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
WO2011138265A2 (en) 2010-05-03 2011-11-10 Evotec Ag Indole and indazole derivatives as orexin receptor antagonists
WO2014152917A2 (en) 2013-03-14 2014-09-25 Janssen Pharmaceutica Nv Physiological ligands for gpr139
JO3719B1 (ar) * 2014-11-20 2021-01-31 Takeda Pharmaceuticals Co 4- أوكسو-4،3- داي هيدرو-3،2،1- بنزوترايازينات كمواد ضابطة لأجل gpr139

Also Published As

Publication number Publication date
NZ732208A (en) 2023-02-24
US10561662B2 (en) 2020-02-18
BR112017010311A2 (pt) 2017-12-26
LT3221298T (lt) 2019-08-12
SI3536324T1 (sl) 2021-12-31
KR102582021B1 (ko) 2023-09-22
PH12017500920B1 (en) 2017-11-20
PL3536324T3 (pl) 2022-02-07
US20200129518A1 (en) 2020-04-30
MY187423A (en) 2021-09-22
MX2017006448A (es) 2017-09-12
SMT202200142T1 (it) 2022-05-12
DOP2017000120A (es) 2017-06-15
HUE044145T2 (hu) 2019-09-30
GEP20196961B (en) 2019-03-25
IL252311B (en) 2020-07-30
US20170095480A1 (en) 2017-04-06
SG11201704002UA (en) 2017-06-29
CY1124929T1 (el) 2023-01-05
HRP20212009T1 (hr) 2022-04-01
JP6637501B2 (ja) 2020-01-29
RS59078B1 (sr) 2019-09-30
EP3221298A1 (en) 2017-09-27
WO2016081736A1 (en) 2016-05-26
US20160145218A1 (en) 2016-05-26
CN112062730B (zh) 2023-09-29
LT3536324T (lt) 2021-12-10
RS62563B1 (sr) 2021-12-31
PH12017500920A1 (en) 2017-11-20
IL252311A0 (en) 2017-07-31
CA2968242C (en) 2022-11-08
MD3221298T2 (ro) 2019-10-31
ES2897545T3 (es) 2022-03-01
CY1122613T1 (el) 2021-05-05
CR20170275A (es) 2017-10-30
AU2015349866A1 (en) 2017-06-15
JO3719B1 (ar) 2021-01-31
CA2968242A1 (en) 2016-05-26
CN112062730A (zh) 2020-12-11
SI3221298T1 (sl) 2019-10-30
PL3221298T3 (pl) 2019-10-31
US20170348319A1 (en) 2017-12-07
TN2017000196A1 (en) 2018-10-19
UA120375C2 (uk) 2019-11-25
US9556130B2 (en) 2017-01-31
US11173161B2 (en) 2021-11-16
MX378158B (es) 2025-03-10
US9770450B2 (en) 2017-09-26
DK3536324T3 (da) 2021-10-25
PT3536324T (pt) 2021-11-10
MA40993B1 (fr) 2019-07-31
DK3221298T3 (da) 2019-06-24
JP6918088B2 (ja) 2021-08-11
AU2015349866B2 (en) 2020-12-03
US10159677B2 (en) 2018-12-25
HRP20191003T1 (hr) 2019-08-23
GEAP201814515A (en) 2018-12-10
KR20170084324A (ko) 2017-07-19
TW201625566A (zh) 2016-07-16
HUE057451T2 (hu) 2022-05-28
EP3536324A1 (en) 2019-09-11
EP3536324B1 (en) 2021-10-06
MA40993A (fr) 2017-09-27
CN107108531A (zh) 2017-08-29
EA033728B1 (ru) 2019-11-20
CN107108531B (zh) 2020-10-20
ES2734735T3 (es) 2019-12-11
JP2020063285A (ja) 2020-04-23
CL2017001292A1 (es) 2018-02-16
EP3221298B1 (en) 2019-04-03
SMT201900355T1 (it) 2019-07-11
ECSP17038999A (es) 2017-10-31
EA201791096A1 (ru) 2017-11-30
JP2017535559A (ja) 2017-11-30
US20190070187A1 (en) 2019-03-07
UY36406A (es) 2016-06-30
CO2017005959A2 (es) 2017-10-20
PE20170899A1 (es) 2017-07-12
TWI684590B (zh) 2020-02-11

Similar Documents

Publication Publication Date Title
PT3221298T (pt) Derivados de 4-oxo-3,4-di-hidro-1,2,3-benzotriazina como moduladores de gpr139
MA42061A (fr) Modulateurs de k-ras
BR112016030368A2 (pt) composição oftálmica
CL2014002755S1 (es) Vehiculo
DK3297438T3 (da) Ccr2-modulatorer
EP2982586A4 (en) VEHICLE
EP2982585A4 (en) VEHICLE
DK3231803T3 (da) Dihydroindolizinonderivat
PT3131898T (pt) Derivados de fluoroalquilfluoreno
ZA201602890B (en) Ethynyl-imidazolin-2,4-dione derivatives as mglur4 modulators
BR112017000035A2 (pt) conjunto de compartimento de articulação
BR112016021869A2 (pt) derivados de fenilpiperidinacarboxamida como fungicidas
EP2982581A4 (en) VEHICLE
EP2982588A4 (en) VEHICLE
PT3303316T (pt) Derivados de etinilo
TH1601004347B (th) ยานพาหนะ
ES1116405Y (es) Maleta de vehiculo
TH1501007892B (th) ยานพาหนะ
TH1501007745B (th) ยานพาหนะ
TH1501007744B (th) ยานพาหนะ
TH1501007739B (th) ยานพาหนะ
TH1501007637B (th) ยานพาหนะ
CL2014001586S1 (es) Vehiculo
ES1136182Y (es) Senalizador de peldanos fotoluminiscentes
TH1501006415B (th) ยานพาหนะ